Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229233 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDSLC6A2SLC6A3 | |
| SCHEMBL10515353 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDSLC6A2SLC6A3 | |
| SCHEMBL1812242 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDSLC6A2SLC6A3 | |
| SCHEMBL7453192 | 0.84 | ALDH1A1 (0.41) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL7453188 | 0.84 | ALDH1A1 (0.41) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL8905955 | 0.83 | PPARG (0.45) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL4761971 | 0.83 | PPARG (0.45) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL7448000 | 0.82 | PPARG (0.44) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL7447493 | 0.82 | ALDH1A1 (0.44) | PPARGPPARAALDH1A1MAPTHPGD | |
| SCHEMBL7447497 | 0.82 | ALDH1A1 (0.44) | PPARGPPARAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| EP-1613338-A4 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1613338-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | Joullie, Madeleine M. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004084812-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2004-10-07 | — | — | WO | disclosed |
| US-6030946-A | FUNCTIONS REVERSIBLY, RESULTING IN TIGHT BINDING (LOW DISSOCIATION CONSTANTS) BETWEEN INHIBITOR AND TARGET ENZYME; USED TO TREAT VARIETY OF DISEAES, INCLUDING ARTHRITIS, MUSCULAR DYSTROPHY, INFLAMMATION, TUMOR INVASION, MALERIA | AXYS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0932619-A1 | MACROCYCLIC PEPTIDES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5888971-A | ANTICOAGULANT | ORTHO PHARMACEUTICAL CORPORATION, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| CN-1192219-A | Reversible cysteine protease inhibitors | ARRIS PHARM CORP (US) | 1998-09-02 | — | — | CN | disclosed |
| EP-0832099-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997030080-A1 | MACROCYCLIC PEPTIDES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996040737-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | PPARG 4137/4885PPARA 4222/4885ALDH1A1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.